EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.

The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of ...

Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...

Male sex was also shown to be an independent risk factor for longer hospital stays and increased hospitalization costs at ...

ArriVent BioPharma, Inc. ( (AVBP) ) has released its Q3 earnings. Here is a breakdown of the information ArriVent BioPharma, Inc. presented to ...

Radiopharm Theranostics has received approval from the Australian Ethics Committee for the inclusion of more tumour types ...

The study, which is being conducted under an FDA-approved Investigational Device Exemption application, held by GRAIL, leverages GRAIL's targeted methylation platform to detect ctDNA. With GRAIL's ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant ...